Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients

Published:2020-07 Issue:4 Volume:21 Page:e294-e301
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Rajaram Ravi,Correa Arlene M.,Xu Ting,Nguyen Quynh-Nhu,Antonoff Mara B.,Rice David,Mehran Reza,Roth Jack,Walsh Garrett,Swisher Stephen,Hofstetter Wayne L.,Vaporciyan Ara,Cascone Tina,Tsao Anne S.,Papadimitrakopoulou Vassiliki A.,Gandhi Saumil,Liao Zhongxing,Sepesi Boris

Funder

MD Anderson Cancer Center

Boehringer Ingelheim

Bristol-Myers Squibb

Ariad

Boehringer-Ingelheim

Astra-Zeneca

Lilly

Millennium

Seattle Genetics

Polaris

Epizyme

Merck

Eli Lilly & Co

Novartis

Astra Zeneca Pharmaceuticals

F. Hoffman-La Roche

Nektar Therapeutics

Janssen

Checkmate

Incyte

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Trends in stage distribution for patients with non–small cell lung cancer: a National Cancer Database survey;Morgensztern;J Thorac Oncol,2010

2. Management of stage IIIA (N2) non–small cell lung cancer;Gillaspie;Thorac Surg Clin,2016

3. Management of stage IIIA (N2) non–small cell lung cancer: a transatlantic perspective;Rocco;Ann Thorac Surg,2016

4. Therapeutic management options for stage III non–small cell lung cancer;Yoon;World J Clin Oncol,2017

5. The eighth edition lung cancer stage classification;Detterbeck;Chest,2017

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial;eClinicalMedicine;2024-02

2. Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process;Current Oncology;2023-12-06

3. Artificial intelligence predicts lung cancer radiotherapy response: A meta-analysis;Artificial Intelligence in Medicine;2023-08

4. Definitive intensity modulated proton re-irradiation for lung cancer in the immunotherapy era;Frontiers in Oncology;2023-01-17

5. Role of Pneumonectomy in T1–4N2M0 Non-Small Cell Lung Cancer: A Propensity Score Matching Analysis;Frontiers in Oncology;2022-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3